STOCK TITAN
  1. Home
  2. News
  3. MNPR

Monopar Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler D. Robinson, MD, Chief Executive Officer, is planning to present a Company overview at the following investor conferences in March:

H.C. Wainwright Global Life Sciences Conference
The Company’s presentation will be webcast on Tuesday, March 9, 2021 at 7:00 a.m. ET

33rd Annual Roth Conference, Healthcare
The Company’s fireside chat will be webcast on Tuesday, March 16, 2021 at 12:00 p.m. ET

Maxim’s 2021 Emerging Growth Virtual Conference
Presentation time to be determined on Wednesday, March 17, 2021

About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar’s pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19. For more information, visit: www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc:
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com

Follow Monopar on social media for updates:

Twitter: @MonoparTx    LinkedIn: Monopar Therapeutics


Stock MNPR logo
Monopar Therapeutics Inc.

NASDAQ:MNPR

MNPR Rankings

#5351 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

MNPR Latest News

Apr 18, 2024
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
Apr 16, 2024
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
Apr 10, 2024
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
Mar 28, 2024
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
Mar 5, 2024
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

MNPR Stock Data

11.35M
8.31M
52.35%
1.55%
0.98%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
WILMETTE

About MNPR

monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.